Evidence map›Paper›PMID 10594038›Full record

ArticleMolecular and cellular biology2000

E2F is required to prevent inappropriate S-phase entry of mammalian cells.

S He, B L Cook, B E Deverman, U Weihe, F Zhang, V Prachand, J Zheng, S J Weintraub

Abstract read
In one paragraph

Article in Molecular and cellular biology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Biomaterials for Mimicking and Modelling Tumor Microenvironment.Advances in experimental medicine and biology · 2022
    Review
  6. Article
  7. Review
  8. Article
  9. Proapoptotic role of novel gene-expression factors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2007
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F.Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research · 2000
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

S HeDepartment of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
B L Cook
B E Deverman
U Weihe
F Zhang
V Prachand
J Zheng
S J Weintraub

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

E2F is a family of transcription factors that regulates the cell cycle. It is widely accepted that E2F-mediated transactivation of a set of genes is the critical activity that governs cellular progression through G(1) into S phase. In contrast to this hypothesis, we demonstrate that E2F actually suppresses the onset of S phase in two cell types when the cells are arrested by gamma irradiation. Our findings indicate that in these cells, the critical event triggering progression from G(0)/G(1) arrest into S phase is the release of E2F-mediated transrepression of cell cycle genes, not transactivation by E2F. Furthermore, our data suggest that E2F-mediated transactivation is not necessary for the G(1)/S-phase transition in these cells.

Indexed as

Carrier ProteinsCell Cycle ProteinsDNA-Binding ProteinsGene Expression RegulationAnimalsCell CycleCells, CulturedE2F Transcription FactorsRetinoblastoma-Binding Protein 1S PhaseTranscription FactorsCarrier ProteinsCell Cycle ProteinsDNA-Binding ProteinsE2F Transcription FactorsRetinoblastoma-Binding Protein 1Transcription Factors

Identifiers

PMID10594038
PMCPMC85091

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.